Alvotech And Stada Gain Second Ever Higher-Strength Adalimumab Nod
Hukyndra And Libmyris Biosimilar Rivals To Humira Endorsed By EMA’s CHMP
Executive Summary
Alvotech and Stada are on the verge of gaining the world’s second ever approval for a higher-strength Humira biosimilar, after the EMA’s CHMP endorsed the firms’ adalimumab under the names Hukyndra and Libmyris at its September meeting.